Corbus Pharmaceuticals Holdings, Inc.

Greetings, and welcome to the Corbis Pharmaceuticals quarterly update conference call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Ted Jenkins, Senior Director, Investor Relations and Corporate Communications. Please go ahead, sir.

Thank you, Kevin. Good morning, everyone. At this time, I'd like to remind our listeners that remarks made during this call may state management's intentions, hopes, beliefs, expectations, or projections of the future. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on Corbis' current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such formative statements are discussed in the periodic reports Corbis files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Joining me on the call today are Dr. Yuval Cohen, our Chief Executive Officer, Dr. Barbara White, our Chief Medical Officer and Head of Research, Sean Moran, our Chief Financial Officer, and Craig Millian, our Chief Commercial Officer. With that, it is my pleasure to turn the call over to you all.

Thank you, Ted. Good morning, everyone. It is my pleasure to welcome everyone to Corbis Pharmaceutical's first quarter 2020 earnings conference call. We had an active first quarter and are on track for an exciting year. We anticipate multiple catalysts and data readouts in the coming months. First, top-line Linavisin data from the Resolve1 Phase 3 study in systemic sclerosis remains on schedule and will be available, and will be available this summer. These data will be followed by top line data from our phase two B lannabism study in cystic fibrosis. With these critical data readouts now closer than ever, we are focusing more and more on preparing our NDA submission and commercialization following FDA approval. We are also on track with our CRB 4001 phase one study that will start later this year as well, as a selection of our next candidate also scheduled for later this year. I would now like to turn the call over to our Chief Medical Officer and Head of Research, Dr. Barbara White, to provide us with an update on our clinical and research program. Thank you, Barbara.